Liquid Biopsy Market to Attain Valuation USD 26.2 Billion by 2030

The global Liquid Biopsy Market size is estimated to generate revenues of more than USD 26.2 billion by 2030, growing at a CAGR of around 14% from 2022 to 2030

The report covers SWOT analysis, market valuation, competitive spectrum, regional share, and revenue predictions. The report offers an analysis of the global liquid biopsy Market for the period 2017 to 2030, wherein 2022 to 2030 is the forecast period and 2021 is considered as the base year.

The wide application portfolio of liquid biopsy market is one of factors driving the growth of market worldwide. The global market is moderately competitive with a blend of global and regional players. The markets key players invest significantly in R and D to enhance their offerings. The entire ecosystem is composed of multiple participants. Every participant of the ecosystem is an equal contributor to the growth of global market.

Why should you invest in this report?

If you are aiming to enter the global liquid biopsy Market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for liquid biopsy are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2022-2030, so that you can plan your strategies to enter this market accordingly. Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.

Report Structure:

• pertinent market numbers of the global liquid biopsy market along with the CAGR for the forecast period 2022-2030
• detailed definitions of different types of liquid biopsy, which gives clarity about what this market is all about and also defines the scope of this report
• macroeconomic factors influencing the global liquid biopsy market, along with market opportunity analysis
• key trends likely to impact the global liquid biopsy market
• PESTLE analysis of all the regions as per the market taxonomy
• Porter’s Five Force Analysis of all the regions as given in the market taxonomy

Global market analysis and forecast:

• the global liquid biopsy market analysis and forecast by product type, by application, by region and others
• key market metrics such as the BPS analysis, year-on-year growth rates, absolute dollar opportunity and market attractiveness analysis of the global liquid biopsy market

Regional market analysis and forecast:

• Regional liquid biopsy market analysis and forecast
• Regional market dynamics including the drivers, restraints and trends applicable across different regions in the liquid biopsy market along with factors encouraging the growth of this market as well as the factors hampering the growth of this market
• Regional trends – both long term and short term

View Full Report@ https://www.precedenceresearch.com/liquid-biopsy-market

Competitive landscape:

• the competitive landscape of this global report
• information on the various leading companies in the global market
• a dashboard view of the key companies operating in the global market along with their important information and broad strategy adopted to stay as leaders in the global market
• key company profiles along with important information such as company details, company description, product portfolio along with key developments concerning the company and strategic analysis

Some of the prominent players in liquid biopsy market include:

• Bio-Rad Laboratories
• Biocept Inc.
• Guardant Health
• Illumina, Inc.
• F. Hoffmann-La Roche Ltd.
• Johnson & Johnson
• Laboratory Corporation of America Holdings
• MDxHealth SA
• QIAGEN N.V
• Thermo Fisher Scientific Inc.

Market Segmentation:

By Technology

• NGS
• PCR
• FISH
• other

By Workflow

• Sample Preparation
• Library Preparation
• Sequencing
• Data Analysis

By Usage

• RUO
• Clinical

By Types of Sample

• Blood
• Urine
• Saliva
• CerebroSpinal Fluid

By Circulating Biomarker

• Circulating Tumor Cells
• Cell-free DNA
• Circulating Cell-Free RNA
• Exosomes and Extracellular Vesicles
• Others

By Products

• Test/Services
• Kits and Consumable
• Instruments

By Indication Type

• Lung Cancer
• Breast Cancer
• Prostate Cancer
• Colorectal Cancer
• Melanoma
• Other cancers
• Non-Oncology Disorders

By Clinical Application

• Treatment Monitoring
• Prognosis and Recurrence Monitoring
• Treatment Selection
• Diagnosis and Screening

By Geography

• North America
• U.S.
• Canada
• Europe
• U.K.
• Germany
• France
• Asia-Pacific
• China
• India
• Japan
• South Korea
• Malaysia
• Philippines
• Latin America
• Brazil
• Rest of Latin America
• Middle East & Africa (MEA)
• GCC
• North Africa
• South Africa
• Rest of the Middle East & Africa

Research Methodology

In this report, historical data, primary responses and public domain data has been thoroughly analyzed to infer the market size. Revenue of companies operating in the global market has been benchmarked to ascertain the market size for the base year. Macroeconomic indicators such as GDP and industry growth have been considered to determine the market size for the forecast period. The historical growth trend of end-use industries, market participants’ performance, as well as the present macro-economic outlook has been taken into consideration for estimating the overall market trend forecast. This data is then validated using the triangulation method and extensively scrutinized using advanced tools to garner quantitative and qualitative insights into the global liquid biopsy.

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Liquid Biopsy Market 

5.1. COVID-19 Landscape: Liquid Biopsy Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Liquid Biopsy Market, By Technology

8.1. Liquid Biopsy Market, by Technology Type, 2021-2030

8.1.1. PCR

8.1.1.1. Market Revenue and Forecast (2019-2030)

8.1.2. NGS

8.1.2.1. Market Revenue and Forecast (2019-2030)

Chapter 9. Global Liquid Biopsy Market, By Application

9.1. Liquid Biopsy Market, by Application, 2021-2030

9.1.1. Cancer (Lungs Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Others)

9.1.1.1. Market Revenue and Forecast (2019-2030)

9.1.2. Non-Cancer

9.1.2.1. Market Revenue and Forecast (2019-2030)

Chapter 10. Global Liquid Biopsy Market, By Circulating Biomarker 

10.1. Liquid Biopsy Market, by Circulating Biomarker, 2021-2030

10.1.1. Circulating Tumor Cells

10.1.1.1. Market Revenue and Forecast (2019-2030)

10.1.2. Cell-Free DNA

10.1.2.1. Market Revenue and Forecast (2019-2030)

10.1.3. Circulating Tumor DNA

10.1.3.1. Market Revenue and Forecast (2019-2030)

10.1.4. Extracellular Vesicles

10.1.4.1. Market Revenue and Forecast (2019-2030)

10.1.5. Others

10.1.5.1. Market Revenue and Forecast (2019-2030)

Chapter 11. Global Liquid Biopsy Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Technology (2019-2030)

11.1.2. Market Revenue and Forecast, by Application (2019-2030)

11.1.3. Market Revenue and Forecast, by Circulating Biomarker (2019-2030)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Technology (2019-2030)

11.1.4.2. Market Revenue and Forecast, by Application (2019-2030)

11.1.4.3. Market Revenue and Forecast, by Circulating Biomarker (2019-2030)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Technology (2019-2030)

11.1.5.2. Market Revenue and Forecast, by Application (2019-2030)

11.1.5.3. Market Revenue and Forecast, by Circulating Biomarker (2019-2030)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Technology (2019-2030)

11.2.2. Market Revenue and Forecast, by Application (2019-2030)

11.2.3. Market Revenue and Forecast, by Circulating Biomarker (2019-2030)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Technology (2019-2030)

11.2.4.2. Market Revenue and Forecast, by Application (2019-2030)

11.2.4.3. Market Revenue and Forecast, by Circulating Biomarker (2019-2030)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Technology (2019-2030)

11.2.5.2. Market Revenue and Forecast, by Application (2019-2030)

11.2.5.3. Market Revenue and Forecast, by Circulating Biomarker (2019-2030)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Technology (2019-2030)

11.2.6.2. Market Revenue and Forecast, by Application (2019-2030)

11.2.6.3. Market Revenue and Forecast, by Circulating Biomarker (2019-2030)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Technology (2019-2030)

11.2.7.2. Market Revenue and Forecast, by Application (2019-2030)

11.2.7.3. Market Revenue and Forecast, by Circulating Biomarker (2019-2030)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Technology (2019-2030)

11.3.2. Market Revenue and Forecast, by Application (2019-2030)

11.3.3. Market Revenue and Forecast, by Circulating Biomarker (2019-2030)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Technology (2019-2030)

11.3.4.2. Market Revenue and Forecast, by Application (2019-2030)

11.3.4.3. Market Revenue and Forecast, by Circulating Biomarker (2019-2030)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Technology (2019-2030)

11.3.5.2. Market Revenue and Forecast, by Application (2019-2030)

11.3.5.3. Market Revenue and Forecast, by Circulating Biomarker (2019-2030)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Technology (2019-2030)

11.3.6.2. Market Revenue and Forecast, by Application (2019-2030)

11.3.6.3. Market Revenue and Forecast, by Circulating Biomarker (2019-2030)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Technology (2019-2030)

11.3.7.2. Market Revenue and Forecast, by Application (2019-2030)

11.3.7.3. Market Revenue and Forecast, by Circulating Biomarker (2019-2030)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Technology (2019-2030)

11.4.2. Market Revenue and Forecast, by Application (2019-2030)

11.4.3. Market Revenue and Forecast, by Circulating Biomarker (2019-2030)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Technology (2019-2030)

11.4.4.2. Market Revenue and Forecast, by Application (2019-2030)

11.4.4.3. Market Revenue and Forecast, by Circulating Biomarker (2019-2030)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Technology (2019-2030)

11.4.5.2. Market Revenue and Forecast, by Application (2019-2030)

11.4.5.3. Market Revenue and Forecast, by Circulating Biomarker (2019-2030)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Technology (2019-2030)

11.4.6.2. Market Revenue and Forecast, by Application (2019-2030)

11.4.6.3. Market Revenue and Forecast, by Circulating Biomarker (2019-2030)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Technology (2019-2030)

11.4.7.2. Market Revenue and Forecast, by Application (2019-2030)

11.4.7.3. Market Revenue and Forecast, by Circulating Biomarker (2019-2030)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Technology (2019-2030)

11.5.2. Market Revenue and Forecast, by Application (2019-2030)

11.5.3. Market Revenue and Forecast, by Circulating Biomarker (2019-2030)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Technology (2019-2030)

11.5.4.2. Market Revenue and Forecast, by Application (2019-2030)

11.5.4.3. Market Revenue and Forecast, by Circulating Biomarker (2019-2030)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Technology (2019-2030)

11.5.5.2. Market Revenue and Forecast, by Application (2019-2030)

11.5.5.3. Market Revenue and Forecast, by Circulating Biomarker (2019-2030)

Chapter 12. Company Profiles

12.1. Bio-Rad Laboratories

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Biocept Inc.

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Guardant Health

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Illumina, Inc.

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. F. Hoffmann-La Roche Ltd.

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Johnson & Johnson

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Laboratory Corporation of America Holdings

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. MDxHealth SA

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. QIAGEN N.V

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Thermo Fisher Scientific Inc.

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms       

Contact Us:

Precedence Research

Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada

Call: +1 9197 992 333      

Email: sales@precedenceresearch.com

Website: https://www.precedenceresearch.com

Blog: http://www.marketstatsnews.com/

Follow us on LinkedIn | Twitter | Facebook